BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Down – Here’s Why

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $7.46, but opened at $7.23. BioCryst Pharmaceuticals shares last traded at $7.43, with a volume of 67,628 shares traded.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on BCRX shares. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.60.

BioCryst Pharmaceuticals Stock Performance

The stock has a 50-day moving average price of $7.61 and a two-hundred day moving average price of $7.41. The stock has a market capitalization of $1.56 billion, a PE ratio of -12.23 and a beta of 1.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period last year, the company earned ($0.19) earnings per share. The business’s revenue for the quarter was up 35.1% on a year-over-year basis. As a group, equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. CWM LLC boosted its stake in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 3,772 shares during the period. Bank of New York Mellon Corp grew its stake in BioCryst Pharmaceuticals by 12.5% during the second quarter. Bank of New York Mellon Corp now owns 775,957 shares of the biotechnology company’s stock valued at $4,795,000 after acquiring an additional 86,249 shares in the last quarter. Leisure Capital Management purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth $173,000. Panagora Asset Management Inc. boosted its holdings in shares of BioCryst Pharmaceuticals by 2.8% during the 2nd quarter. Panagora Asset Management Inc. now owns 650,318 shares of the biotechnology company’s stock valued at $4,019,000 after purchasing an additional 17,759 shares during the last quarter. Finally, Signaturefd LLC grew its position in shares of BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,599 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.